Rebamipide - Otsuka Pharmaceutical

Drug Profile

Rebamipide - Otsuka Pharmaceutical

Alternative Names: Mucosta; OPC-12759; OPC-12759E; OPC759; Pramipide; Proamipide

Latest Information Update: 19 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Otsuka Pharmaceutical
  • Developer Acucela; Otsuka Pharmaceutical
  • Class Amino acids; Antiulcers; Cytoprotectives; Eye disorder therapies; Quinolones; Small molecules
  • Mechanism of Action Oxygen radical formation antagonists; Oxygen radical scavengers; Prostaglandin agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Dry eyes; Gastric ulcer; Gastritis
  • Phase II Stomatitis
  • Discontinued Cancer; Diabetes mellitus; Keratoconjunctivitis; NSAID-induced ulcer; Ulcerative colitis; Xerostomia

Most Recent Events

  • 31 Mar 2017 Rebamipide is still in phase III trials for Dry eyes in Japan (Ophthalmic,Drops,Multi dose) (Otsuka pipeline, March 2017)
  • 06 Jan 2017 Otsuka Pharmaceutical completes a phase II trial in Dry eyes (Neoadjuvant therapy) in Japan (Ophthalmic,Drops,Unit dose) (UMIN000016986)
  • 10 Jun 2016 Otsuka Pharmaceutical initiates a clinical pharmacological trial for Dry eyes in Japan (Ophthalmic) (UMIN000022629)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top